Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 27M | 42M | 24M | 45M | 27M |
| Gross Profit | 12M | 24M | 14M | 30M | 17M |
| Operating Income | -10M | 8M | -382K | 15M | 4M |
| EBITDA | -10M | 9M | 79K | 15M | 5M |
| Net Income | -8M | 7M | 485K | 24M | 4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$2.79
+2.20% today
1Y Change
-39.35%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sensus Healthcare, Inc. (SRTS) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $2.79 and down 39.3% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -34.3%, EPS growth of -214.6%, a dividend yield of 0.0%. What stands out right now is revenue -34.3%, EPS -214.6%, free cash flow +130.0% with operating margin -37.5% and ROIC -17.0%. Valuation is more restrained than many high-expectation growth names at price/sales 2.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SRTS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SRTS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SRTS Max Drawdown
-52.39%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SRTS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$27.0M
-39.3% YoY
FY Net Income
$4.1M
-83.0% YoY
Free Cash Flow
-$414.0K
+73.6% YoY
Revenue Growth
-34.3%
EPS Growth
-214.6%
Gross Margin
43.2%
Net Margin
-28.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 27M | 42M | 24M | 45M | 27M |
| Gross Profit | 12M | 24M | 14M | 30M | 17M |
| Operating Income | -10M | 8M | -382K | 15M | 4M |
| EBITDA | -10M | 9M | 79K | 15M | 5M |
| Net Income | -8M | 7M | 485K | 24M | 4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 22M | 22M | 23M | 26M | 15M |
| Total Assets | 53M | 62M | 54M | 57M | 32M |
| Total Liabilities | 5M | 6M | 5M | 9M | 6M |
| Shareholder Equity | 48M | 56M | 49M | 48M | 26M |
| Total Debt | 680K | 602K | 783K | 1M | 225K |
| Net Debt | -21M | -21M | -22M | -25M | -14M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
286K
+79.7% YoY
Capital Expenditures
128K
+19.5% YoY
Free Cash Flow
414K
+73.6% YoY
Key ratios
Gross Margin
43.2%
Operating Margin
-37.5%
Net Margin
-28.1%
ROE
-15.1%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.